Telavancins interactions with the bacterial cell membrane

Future Microbiology

Volumn 5, Issue 3, 2010, Pages 355-358

  Nannini, Esteban C ^a   Stryjewski, Martin E ^b,c   Corey, G Ralph ^a,b  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CEMIC   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CYCLOSERINE; DAPTOMYCIN; FOSFOMYCIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE TRANSPORT; CONCENTRATION RESPONSE; CYTOLYSIS; DRUG BINDING; DRUG EFFICACY; LIPOGENESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; POLYMERIZATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 77949400687     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.122     Document Type: Note

References (13)

1. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM: Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53, 3375-3383 (2009).
2. Higgins DL, Chang R, Debabov DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005).
3. Hasper HE, Kramer NE, Smith JL et al.: An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313, 1636-1637 (2006).
4. Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1, 147-155 (2001).
5. Van Bambeke F: Glycopeptides in clinical development: pharmacological profle and clinical perspectives. Curr. Opin. Pharmacol. 4, 471-478 (2004).
6. Judice JK, Pace JL: Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13, 4165-4168 (2003).
7. Perkins HR, Nieto M: The chemical basis for the action of the vancomycin group of antibiotics. Ann. NY Acad. Sci. 235, 348-363 (1974).
8. Pace JL, Krause K, Johnston D et al.: In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 3602-3604 (2003).
9. Leuthner KD, Cheung CM, Rybak MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58, 338-343 (2006).
10. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58, 1177-1184 (2006).
11. Sahm D, Draghi D, Benton B, Jones M, Krause K, Thornsberry C: Europe surveillance initiative profling the anti-enterococcal activity of telavancin by specimen source from 2004 to 2005. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany, 31 March-4 April, 2007.
12. Silverman JA, Perlmutter NG, Shapiro HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538-2544 (2003).
13. Nannini EC, Stryjewski ME: A new lipoglycopeptide: telavancin. Expert Opin. Pharmacother. 9, 2197-2207 (2008).